NASDAQ:NRIX
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.'s revenue grew 54.0% in fiscal 2025 to $84.0M while operating margin rose to −340.2%. Free cash flow was −$263.5M, −313.7% of revenue, and the diluted share count rose 29.1%.Summary generated from Nurix Therapeutics, Inc.'s SEC filings. Latest annual report filed Jan 28, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$84.0M
Revenue growth+54.0%
Revenue, 5-yr CAGR+36.3%
Gross marginn/a
Operating margin−340.2%
Net margin−314.9%
ROICn/a
Return on equity−49.6%
Debt / equityn/a
Free cash flow−$263.5M
FCF margin−313.7%
Share count change+29.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 30 | 39 | 77 | 55 | 84 |
| Operating income | −118 | −184 | −155 | −213 | −286 |
| Net income | −117 | −180 | −144 | −194 | −264 |
| Free cash flow | −90 | −172 | −90 | −182 | −263 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended May 31, 2026
Jul 9, 2026 - 8-KResults of operations and financial condition
Jul 9, 2026 - 8-KRegulation FD disclosure
Jun 11, 2026 - 8-KEntry into a material agreement
Jun 8, 2026 - 8-KResults of a shareholder vote
May 15, 2026 - 10-QQuarterly report for the period ended Feb 28, 2026
Apr 8, 2026